Researchers from Diaceutics and the Personalized Medicine Coalition has published a special report in JCO Precision Oncology that provides an in-depth look at United States health systems’ efforts to deploy potentially paradigm-shifting targeted and immuno-oncology drugs to improve care for lung cancer patients.
